2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Approved WMOCompleted
To establish preliminary safety and tolerability of single- and multiple-ascending oral doses of MYK 491 in ambulatory patients with stable heart failure with reduced ejection fraction (HFrEF)